Does Timing of Treatment Have an Effect on Survival in Ovarian Carcinoma?

Yıl 2022, Cilt: 6 Sayı: 3, 877 - 883, 29.09.2022

Hüseyin Salih Semiz , Merve Keskinkılıç , Zülal Arıcı , Ferahnaz Badem , Behzat Can , Muzaffer Sancı

https://doi.org/10.30621/jbachs.1167095

Öz

Background and Purpose: Optimal cytoreduction (CRS) is the main treatment modality in epithelial ovarian cancer (OC). Inoperable OC at the time of diagnosis may become eligible for CRS after neoadjuvant chemotherapy (NACT). We aimed to investigate the effect of the time between NACT-CRS and CRS-adjuvant chemotherapy on survival in OC patients.
Materials and Methods: Demographic and clinicopathological characteristics of sixty-nine patients with OC who underwent CRS after NACT between December 2009 and May 2020 were analyzed retrospectively.
Results: The median age was 61.1, and the median overall survival (OS) was 75.8 months. The median time from the end of NACT to CRS was 6.53 weeks, and the median time from CRS to initiation of adjuvant therapy was 4.8 weeks. The mean OS was 123.4 months in patients with a NACT-CRS interval of 6.53 weeks or less, and it was 61.6 months in patients above this period (p>0.05). The OS was 75.7 months in patients with an interval between CRS and adjuvant therapy of 4.8 weeks or less and 55.1 months compared to those with 4.8 weeks or more (p>0.05).
Conclusion: It was shown numerically, although not statistically significant, that a long time between NACT and CRS and CRS-adjuvant therapy had a negative effect on OS.

Anahtar Kelimeler

Adjuvant Chemotherapy, Cytoreductive Surgery, Neoadjuvant Chemotherapy, Ovarian Cancer

Proje Numarası

Yok

Kaynakça

• 1. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1:61-85. doi:10.1002/ijgo.13878.
• 1. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1:61-85. doi:10.1002/ijgo.13878.
• 2. Park SJ, Kim J, Kim SN et al. Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. Jpn J Clin Oncol. 2019 Feb 1;49(2):137-145. DOI: 10.1093/jjco/hyy175. PMID: 30521037.
• 2. Park SJ, Kim J, Kim SN et al. Practice patterns of surgery for advanced ovarian cancer: analysis from international surveys. Jpn J Clin Oncol. 2019 Feb 1;49(2):137-145. DOI: 10.1093/jjco/hyy175. PMID: 30521037.
• 3. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. Published 2020 Nov 9. doi:10.1136/BMJ.m3773.
• 3. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. Published 2020 Nov 9. doi:10.1136/BMJ.m3773.
• 4. Huang CY, Cheng M, Lee NR et al. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. Int J Environ Res Public Health. 2020 Mar 26;17(7):2213. DOI: 10.3390/ijerph17072213. PMID: 32224896; PMCID: PMC7177627.
• 4. Huang CY, Cheng M, Lee NR et al. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. Int J Environ Res Public Health. 2020 Mar 26;17(7):2213. DOI: 10.3390/ijerph17072213. PMID: 32224896; PMCID: PMC7177627.
• 5. Elies A, Rivière S, Pouget N et al. The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2018 Jun;18(6):555-566. doi: 10.1080/14737140.2018.1458614. Epub 2018 Apr 10. PMID: 29633903.
• 5. Elies A, Rivière S, Pouget N et al. The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2018 Jun;18(6):555-566. doi: 10.1080/14737140.2018.1458614. Epub 2018 Apr 10. PMID: 29633903.
• 6. Fagotti A, Ferrandina MG, Vizzielli G et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. DOI: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7. PMID: 33028623.
• 6. Fagotti A, Ferrandina MG, Vizzielli G et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. DOI: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7. PMID: 33028623.
• 7. Minareci Y, Sozen H, Ak N et al. Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer. Chemotherapy. 2022;67(1):1-11. DOI: 10.1159/000519615. Epub 2021 Nov 16. PMID: 34784598.
• 7. Minareci Y, Sozen H, Ak N et al. Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer. Chemotherapy. 2022;67(1):1-11. DOI: 10.1159/000519615. Epub 2021 Nov 16. PMID: 34784598.
• 8. Timmermans M, van der Aa MA, Lalisang RI et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol. 2018 Sep;150(3):446-450. DOI: 10.1016/j.ygyno.2018.07.004. Epub 2018 Jul 9. PMID: 30001834.
• 8. Timmermans M, van der Aa MA, Lalisang RI et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol. 2018 Sep;150(3):446-450. DOI: 10.1016/j.ygyno.2018.07.004. Epub 2018 Jul 9. PMID: 30001834.
• 9. Lee YY, Lee JW, Lu L et al. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynaecol Obstet. 2018 Dec;143(3):325-332. DOI: 10.1002/ijgo.12653. Epub 2018 Sep 19. PMID: 30129040.
• 9. Lee YY, Lee JW, Lu L et al. Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynaecol Obstet. 2018 Dec;143(3):325-332. DOI: 10.1002/ijgo.12653. Epub 2018 Sep 19. PMID: 30129040.
• 10. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan;27(1):114-21. DOI: 10.1093/annonc/mdv500. Epub 2015 Oct 20. PMID: 26487588; PMCID: PMC4684156.
• 10. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan;27(1):114-21. DOI: 10.1093/annonc/mdv500. Epub 2015 Oct 20. PMID: 26487588; PMCID: PMC4684156.
• 11. Hofstetter G, Concin N, Braicu I et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013 Oct;131(1):15-20. DOI: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20. PMID: 23877013.
• 11. Hofstetter G, Concin N, Braicu I et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013 Oct;131(1):15-20. DOI: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20. PMID: 23877013.
• 12. Lee YJ, Chung YS, Lee JY et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecol Oncol. 2018 Jan;148(1):62-67. DOI: 10.1016/j.ygyno.2017.11.023. Epub 2017 Nov 22. PMID: 29174056.
• 12. Lee YJ, Chung YS, Lee JY et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer. Gynecol Oncol. 2018 Jan;148(1):62-67. DOI: 10.1016/j.ygyno.2017.11.023. Epub 2017 Nov 22. PMID: 29174056.
• 13. Liu YL, Zhou QC, Iasonos A et al. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Int J Gynecol Cancer. 2020 Oct;30(10):1554-1561. DOI: 10.1136/ijgc-2019-000989. Epub 2020 Jun 9. PMID: 32522770.
• 13. Liu YL, Zhou QC, Iasonos A et al. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. Int J Gynecol Cancer. 2020 Oct;30(10):1554-1561. DOI: 10.1136/ijgc-2019-000989. Epub 2020 Jun 9. PMID: 32522770.
• 14. Wang D, Zhang G, Peng C, Shi Y, Shi X. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2021 Mar 27;14(1):49. DOI: 10.1186/s13048-021-00801-4. PMID: 33771198; PMCID: PMC8004423.
• 14. Wang D, Zhang G, Peng C, Shi Y, Shi X. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2021 Mar 27;14(1):49. DOI: 10.1186/s13048-021-00801-4. PMID: 33771198; PMCID: PMC8004423.
• 15. Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. J Ovarian Res. 2014 Apr 22;7:41. DOI: 10.1186/1757-2215-7-41. PMID: 24834130; PMCID: PMC4022349.
• 15. Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. J Ovarian Res. 2014 Apr 22;7:41. DOI: 10.1186/1757-2215-7-41. PMID: 24834130; PMCID: PMC4022349.
• 16. Kotsopoulos J, Moody JR, Fan I et al.SA. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol. 2012 Oct;127(1):83-7. DOI: 10.1016/j.ygyno.2012.05.038. Epub 2012 Jun 16. PMID: 22713293.
• 16. Kotsopoulos J, Moody JR, Fan I et al.SA. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol. 2012 Oct;127(1):83-7. DOI: 10.1016/j.ygyno.2012.05.038. Epub 2012 Jun 16. PMID: 22713293.
• 17. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Guideline (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 12, 2022.
• 17. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Guideline (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 12, 2022.
• 18. Akilli H, Rahatli S, Tohma YA, Karakas LA, Altundag O, Ayhan A. Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced-stage epithelial ovarian cancer. J BUON. 2018 Dec;23(7):111-115. PMID: 30722119.
• 18. Akilli H, Rahatli S, Tohma YA, Karakas LA, Altundag O, Ayhan A. Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced-stage epithelial ovarian cancer. J BUON. 2018 Dec;23(7):111-115. PMID: 30722119.
• 19. Liu YL, Zhou QC, Iasonos A et al. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020 Dec;30(12):1915-1921. DOI: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26. PMID: 33106271; PMCID: PMC8407101.
• 19. Liu YL, Zhou QC, Iasonos A et al. Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. Int J Gynecol Cancer. 2020 Dec;30(12):1915-1921. DOI: 10.1136/ijgc-2020-001641. Epub 2020 Oct 26. PMID: 33106271; PMCID: PMC8407101.
• 20. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259. DOI: 10.1093/annonc/mdy157. Erratum for: Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32. PMID: 30285216.
• 20. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259. DOI: 10.1093/annonc/mdy157. Erratum for: Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32. PMID: 30285216.